177 related articles for article (PubMed ID: 17325735)
1. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
2. Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?
Fernández-Santander A; Santiago C; Díez-Durán S; González M; de Castro E; Guijarro J; Bandrés F; Lucia A; Gómez-Gallego F
Hum Psychopharmacol; 2008 Aug; 23(6):533-6. PubMed ID: 18425996
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
6. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
7. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients.
Ouerhani S; Marrakchi R; Bouhaha R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Bull Cancer; 2008 Feb; 95(2):E1-4. PubMed ID: 18304900
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
9. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
10. C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients.
Hoenicka J; Aragüés M; Rodríguez-Jiménez R; Ponce G; Martínez I; Rubio G; Jiménez-Arriero MA; Palomo T;
Acta Psychiatr Scand; 2006 Dec; 114(6):435-8. PubMed ID: 17087792
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 gene test in psychiatric patients and healthy volunteers.
Rasmussen JO; Christensen M; Svendsen JM; Skausig O; Hansen EL; Nielsen KA
Scand J Clin Lab Invest; 2006; 66(2):129-36. PubMed ID: 16537246
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes.
Alvarez S; Mas S; Gassó P; Bernardo M; Parellada E; Lafuente A
Fundam Clin Pharmacol; 2010 Dec; 24(6):741-7. PubMed ID: 20041956
[TBL] [Abstract][Full Text] [Related]
15. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype.
Chen SQ; Wedlund PJ
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):585-8. PubMed ID: 10678117
[TBL] [Abstract][Full Text] [Related]
16. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
17. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers.
Peñas-LLedó EM; Dorado P; Pacheco R; González I; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1111-20. PubMed ID: 19604084
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
19. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
